Matrix Metalloproteinase-9 rs17576 Gene Polymorphism and Behçet’s Disease: Is There an Association?

References

• Abilleira S, Sitzer M, Markus HS, Bevan S. 2007. Polymorphisms in MMP family andTIMP genes and carotid artery intima-media thickness Christine Armstrong. Stroke, 38, 2895–9.
   PubMed Web of Science ®Google Scholar
• Aksoy Y, Ercan A, Dalmizrak O, et al. 2011. The determination of matrix metalloproteinase 9 activity and gene expression levels in Behcet’s disease patients with aneurysmal complications. Clin Rheumatol, 30, 515–19.
   PubMed Web of Science ®Google Scholar
• Allan JA, Docherty AJ, Barker PJ, et al. 1995. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J, 309, 299–306.
   PubMed Web of Science ®Google Scholar
• Belo VA, Souza-Costa DC, Luizon MR, et al. 2012. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obesity, 36(1),69–75.
   Web of Science ®Google Scholar
• Campbell IL, Pagenstecher A. 1999. Matrix metalloproteinases and their inhibitors in the nervous system: the good, the bad and the enigmatic, Trends Neurosci, 22, 285–7.
   Google Scholar
• Cantarini L, Lopalco G, Caso F, et al. 2015. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease, Autoimmunity Rev, 14, 1–9.
   PubMed Web of Science ®Google Scholar
• Chiang TY, Shyu LY, Tsao TC, et al. 2012. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin Chem Lab Med, 50(3),449–54.
   Web of Science ®Google Scholar
• Choke E, Thompson MM, Dawson J, et al. 2006. Abdominal aortic aneurysm rupture is associated with increased medial neovascularization and overexpression of proangiogenic cytokines. Arterioscler Thromb Vasc Biol, 26, 2077–82.
   PubMed Web of Science ®Google Scholar
• Corbel M, Belleguic C, Boichot E, Lagente V. 2002. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway infl ammation and pulmonary fi brosis. Cell Biol Toxicol, 18, 51–61.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Assaad-Khalil S, Calamia K, et al. 2014. The International criteria for Behçet’s disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol, 28, 338–47.
   PubMed Web of Science ®Google Scholar
• Delclaux C, Delacourt C, D’Ortho MP, et al. 1996. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol, 14(3),288–95.
   PubMed Web of Science ®Google Scholar
• Durrani O, Banahan K, Sheedy FJ, et al. 2011. TIRAP Ser180Leu polymorphism is associated with Behcet’s disease. Rheumatology (Oxford), 50, 1760–5.
   PubMed Web of Science ®Google Scholar
• Elmore JR, Keister BF, Franklin DP, et al. 1998. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg, 12, 221–8.
   PubMed Web of Science ®Google Scholar
• Fanjul-Fernandez M, Folgueras AR, Cabrera S, et al. 2010. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta, 1803, 3–19.
   PubMed Web of Science ®Google Scholar
• Ganeb SS, Kamal HM, Fayed AA. 2012. Pathogenetic role of matrix Metalloproteinase-2 and Matrixmetalloproteinase-9 in Behcet’s disease. Life Sci J, 9(3), 706–712.
   Google Scholar
• Hamzaoui K, Maitre B, Hamzaoui A. 2009. Elevated levels of MMP-9 and TIMP-1in the cerebrospinal fluid of neuro-BD. Clin Exp Rheumatol, 27, S52–7.
   PubMed Web of Science ®Google Scholar
• Hu Z, Huo X, Lu D. 2005. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. Clin CancerRes, 11:5433–9.
   PubMed Web of Science ®Google Scholar
• Johnson LL, Dyer R, Hupe DJ. 1998. Matrix metalloproteinases. Curr Opin Chem Biol, 2, 466–71.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Kang SW, Baek HJ, et al. 2010. Association between matrix metalloproteinase 9 promoter polymorphisms and Behc¸et’s disease. Hum Immunol, 71, 717–22.
   PubMed Web of Science ®Google Scholar
• Lo¨ffek S, Schilling O, Franzke C. 2011. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J, 38, 191–208.
   PubMed Web of Science ®Google Scholar
• Massova I, Fridman R, Mobashery S. 1997. Structural insight into the catalytic domains of human matrix metalloprotease-2 and human matrix metalloprotease-9: implications for substrate specificities. J Mol Mod, 3, 17–30.
   Web of Science ®Google Scholar
• Nagase H, Woessner JF. 1999. Matrix metalloproteinases. J Biol Chem, 274(31),21491–4.
   PubMed Web of Science ®Google Scholar
• Naouali A, Kaabachi W, Tizaoui K, et al. 2015. Association of MMP-9 gene polymorphisms with Behçet’s disease risk. Immunol Lett, 164(1),18–24.
   PubMed Web of Science ®Google Scholar
• O’Farrell TJ, Pourmotabbed T. 2000. Identification of structural elements importantfor matrix metalloproteinase type V collagenolytic activity as revealed bychimeric enzymes. Role of fibronectin-like domain and active site of gelatinaseB. J Biol Chem, 275, 27964–72.
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Van den Steen PE, Dubois B, et al. 2001. MMP-9 functions as regulator and effector in leukocyte biology. J Leukocyte Biol, 69(6),851–9.
   PubMed Web of Science ®Google Scholar
• Park KS, Min Y, Park SR, et al. 2012. Matrixmetalloproteinase-2, -9, -12, and tissue inhibitor of metalloproteinase 2 genepolymorphisms and cutaneous expressions in patients with BD. Tissue Antigens, 79, 333–9.
   PubMedGoogle Scholar
• Park YW, Park JJ, Lee JB, Lee SS. 2006. Development of Henoch–Schonlein purpura in a patient with Behcet’s disease presenting with recurrent deep vein thrombosis. Clin Exp Rheumatol, 25(4 Suppl 45), S96–8.
   Web of Science ®Google Scholar
• Pay S, Abbasov T, Erdem H, et al. 2007. Serum MMP-2and MMP-9 in patients with BD: do their higher levels corre-late to vasculo-BD associated with aneurysm formation. Clin ExpRheumatol, 25, S70.
   Web of Science ®Google Scholar
• Pyo R, Lee JK, Shipley JM, et al. 2000. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest, 105(11),1641–9.
   PubMed Web of Science ®Google Scholar
• Renckens R, Roelofs JJ, Florquin S, et al. 2006. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J Immunol, 176, 3735–41.
   PubMed Web of Science ®Google Scholar
• Sakane T, Takeno M, Suzuki N, Inaba G. 1999. Behçet’s disease. N Engl J Med, 341, 1284–91.
   PubMed Web of Science ®Google Scholar
• Sole´ X, Guino´ E, Valls J, et al. 2006. SNPStats: a web tool for the analysis of association studies. Bioinformatics, 22(15),1928–9.
   PubMed Web of Science ®Google Scholar
• Vandooren J, Van den Steen PE, Opdenakker G. 2013. Biochemistry and molecular biology of gelatinase B or MMP-9: the nextdecade. Crit Rev Biochem Mol Biol, 48, 222–72.
   PubMed Web of Science ®Google Scholar
• Wu H, Bai X, Chen D, et al. 2013. Association of genetic polymorphisms in matrix Metalloproteinase-9 and coronary artery disease in the chinese han population: A case–control study. Genet Test Mol Biomarkers, 17(9),707–12. doi:10.1089/gtmb.2013.0109.
   PubMed Web of Science ®Google Scholar
• Zhang B, Henney A, Eriksson P, et al. 1999. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet, 105, 418–23.
   PubMed Web of Science ®Google Scholar